|
Title
|
|
|
|
-methylguanine-DNA methyltransferase (MGMT) : a drugable target in lung cancer?
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| This manuscript addresses the role of O6-methylguanine-DNA methyltransferase (MGMT) as a biomarker in the oncogenesis of cancer and the opportunity of turning this gene into a drugable target in neuroendocrine tumours of the lung. Studies in brain tumours conclude that MGMT promoter methylation is considered a strong predictive factor for a favourable outcome for treatment with temozolomide, e.g. alkylating agent. We conducted a systematic review of MGMT in non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) and other pulmonary neuroendocrine tumours (NETs) to evaluate whether MGMT is a prognostic and/or predictive factor to select patients with lung cancer who can benefit from treatment with temozolomide. In NSCLC MGMT promoter methylation is not a prognostic and predictive factor, hence temozolomide has no place. In SCLC and NET patients with a MGMT promoter methylation benefit of temozolomide has to be confirmed.Temozolomide can be considered a personalized treatment if the predictive role of MGMT is further confirmed. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Lung cancer: journal of the International Association for the Study of Lung Cancer / International Association for the Study of Lung Cancer [Aurora, Colo.] - Amsterdam
|
|
|
Publication
|
|
|
|
Amsterdam
:
2017
|
|
|
ISSN
|
|
|
|
0169-5002
|
|
|
DOI
|
|
|
|
10.1016/J.LUNGCAN.2016.07.014
|
|
|
Volume/pages
|
|
|
|
107
(2017)
, p. 91-99
|
|
|
ISI
|
|
|
|
000400213900011
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|